nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—ovarian cancer	0.699	1	CbGbCtD
Lubiprostone—CLCN2—epithelium—ovarian cancer	0.0141	0.112	CbGeAlD
Lubiprostone—CLCN2—gonad—ovarian cancer	0.0117	0.0929	CbGeAlD
Lubiprostone—CLCN2—uterus—ovarian cancer	0.0116	0.0923	CbGeAlD
Lubiprostone—CLCN2—female reproductive system—ovarian cancer	0.0105	0.083	CbGeAlD
Lubiprostone—CLCN2—vagina—ovarian cancer	0.00946	0.0751	CbGeAlD
Lubiprostone—CLCN2—testis—ovarian cancer	0.00844	0.067	CbGeAlD
Lubiprostone—CBR1—myometrium—ovarian cancer	0.00719	0.0571	CbGeAlD
Lubiprostone—CBR1—Vincristine—Vinorelbine—ovarian cancer	0.00644	1	CbGdCrCtD
Lubiprostone—CLCN2—lymph node—ovarian cancer	0.00612	0.0485	CbGeAlD
Lubiprostone—CBR1—uterine cervix—ovarian cancer	0.00559	0.0444	CbGeAlD
Lubiprostone—CBR1—decidua—ovarian cancer	0.00533	0.0423	CbGeAlD
Lubiprostone—CBR1—endometrium—ovarian cancer	0.00506	0.0402	CbGeAlD
Lubiprostone—CBR1—gonad—ovarian cancer	0.00469	0.0373	CbGeAlD
Lubiprostone—CBR1—uterus—ovarian cancer	0.00466	0.037	CbGeAlD
Lubiprostone—CBR1—female reproductive system—ovarian cancer	0.00419	0.0333	CbGeAlD
Lubiprostone—CBR1—bone marrow—ovarian cancer	0.00396	0.0314	CbGeAlD
Lubiprostone—CBR1—female gonad—ovarian cancer	0.00381	0.0303	CbGeAlD
Lubiprostone—CBR1—vagina—ovarian cancer	0.00379	0.0301	CbGeAlD
Lubiprostone—CBR1—testis—ovarian cancer	0.00338	0.0268	CbGeAlD
Lubiprostone—CBR1—lymph node—ovarian cancer	0.00245	0.0195	CbGeAlD
Lubiprostone—Hypersensitivity—Chlorambucil—ovarian cancer	0.000513	0.00304	CcSEcCtD
Lubiprostone—Feeling abnormal—Topotecan—ovarian cancer	0.000511	0.00303	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Topotecan—ovarian cancer	0.000507	0.00301	CcSEcCtD
Lubiprostone—Anorexia—Vinorelbine—ovarian cancer	0.000506	0.003	CcSEcCtD
Lubiprostone—Asthenia—Chlorambucil—ovarian cancer	0.0005	0.00296	CcSEcCtD
Lubiprostone—Oedema peripheral—Paclitaxel—ovarian cancer	0.000495	0.00293	CcSEcCtD
Lubiprostone—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000494	0.00293	CcSEcCtD
Lubiprostone—Abdominal pain—Topotecan—ovarian cancer	0.00049	0.00291	CcSEcCtD
Lubiprostone—Weight increased—Docetaxel—ovarian cancer	0.000484	0.00287	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000484	0.00287	CcSEcCtD
Lubiprostone—Diarrhoea—Chlorambucil—ovarian cancer	0.000477	0.00283	CcSEcCtD
Lubiprostone—Dyspnoea—Vinorelbine—ovarian cancer	0.000473	0.00281	CcSEcCtD
Lubiprostone—Decreased appetite—Vinorelbine—ovarian cancer	0.000461	0.00274	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000458	0.00272	CcSEcCtD
Lubiprostone—Fatigue—Vinorelbine—ovarian cancer	0.000458	0.00271	CcSEcCtD
Lubiprostone—Hypersensitivity—Topotecan—ovarian cancer	0.000457	0.00271	CcSEcCtD
Lubiprostone—Constipation—Vinorelbine—ovarian cancer	0.000454	0.00269	CcSEcCtD
Lubiprostone—Pain—Vinorelbine—ovarian cancer	0.000454	0.00269	CcSEcCtD
Lubiprostone—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000453	0.00268	CcSEcCtD
Lubiprostone—Hypersensitivity—Melphalan—ovarian cancer	0.000448	0.00265	CcSEcCtD
Lubiprostone—Asthenia—Topotecan—ovarian cancer	0.000445	0.00264	CcSEcCtD
Lubiprostone—Vomiting—Chlorambucil—ovarian cancer	0.000443	0.00263	CcSEcCtD
Lubiprostone—Mental disorder—Paclitaxel—ovarian cancer	0.00044	0.00261	CcSEcCtD
Lubiprostone—Malnutrition—Paclitaxel—ovarian cancer	0.000437	0.00259	CcSEcCtD
Lubiprostone—Erythema—Paclitaxel—ovarian cancer	0.000437	0.00259	CcSEcCtD
Lubiprostone—Feeling abnormal—Vinorelbine—ovarian cancer	0.000437	0.00259	CcSEcCtD
Lubiprostone—Asthenia—Melphalan—ovarian cancer	0.000436	0.00258	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000434	0.00257	CcSEcCtD
Lubiprostone—Flatulence—Paclitaxel—ovarian cancer	0.000431	0.00256	CcSEcCtD
Lubiprostone—Dysgeusia—Paclitaxel—ovarian cancer	0.000428	0.00254	CcSEcCtD
Lubiprostone—Diarrhoea—Topotecan—ovarian cancer	0.000425	0.00252	CcSEcCtD
Lubiprostone—Lethargy—Epirubicin—ovarian cancer	0.000424	0.00251	CcSEcCtD
Lubiprostone—Muscle spasms—Paclitaxel—ovarian cancer	0.000421	0.00249	CcSEcCtD
Lubiprostone—Abdominal pain—Vinorelbine—ovarian cancer	0.00042	0.00249	CcSEcCtD
Lubiprostone—Oedema peripheral—Docetaxel—ovarian cancer	0.00042	0.00249	CcSEcCtD
Lubiprostone—Connective tissue disorder—Docetaxel—ovarian cancer	0.000419	0.00248	CcSEcCtD
Lubiprostone—Diarrhoea—Melphalan—ovarian cancer	0.000416	0.00246	CcSEcCtD
Lubiprostone—Nausea—Chlorambucil—ovarian cancer	0.000414	0.00245	CcSEcCtD
Lubiprostone—Dizziness—Topotecan—ovarian cancer	0.00041	0.00243	CcSEcCtD
Lubiprostone—Tremor—Paclitaxel—ovarian cancer	0.00041	0.00243	CcSEcCtD
Lubiprostone—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000406	0.00241	CcSEcCtD
Lubiprostone—Vomiting—Topotecan—ovarian cancer	0.000394	0.00234	CcSEcCtD
Lubiprostone—Malaise—Paclitaxel—ovarian cancer	0.000394	0.00234	CcSEcCtD
Lubiprostone—Syncope—Paclitaxel—ovarian cancer	0.000392	0.00233	CcSEcCtD
Lubiprostone—Lethargy—Doxorubicin—ovarian cancer	0.000392	0.00232	CcSEcCtD
Lubiprostone—Rash—Topotecan—ovarian cancer	0.000391	0.00232	CcSEcCtD
Lubiprostone—Hypersensitivity—Vinorelbine—ovarian cancer	0.000391	0.00232	CcSEcCtD
Lubiprostone—Dermatitis—Topotecan—ovarian cancer	0.000391	0.00232	CcSEcCtD
Lubiprostone—Headache—Topotecan—ovarian cancer	0.000389	0.0023	CcSEcCtD
Lubiprostone—Palpitations—Paclitaxel—ovarian cancer	0.000387	0.00229	CcSEcCtD
Lubiprostone—Vomiting—Melphalan—ovarian cancer	0.000386	0.00229	CcSEcCtD
Lubiprostone—Loss of consciousness—Paclitaxel—ovarian cancer	0.000384	0.00228	CcSEcCtD
Lubiprostone—Mediastinal disorder—Docetaxel—ovarian cancer	0.000384	0.00228	CcSEcCtD
Lubiprostone—Rash—Melphalan—ovarian cancer	0.000383	0.00227	CcSEcCtD
Lubiprostone—Dermatitis—Melphalan—ovarian cancer	0.000383	0.00227	CcSEcCtD
Lubiprostone—Cough—Paclitaxel—ovarian cancer	0.000382	0.00226	CcSEcCtD
Lubiprostone—Asthenia—Vinorelbine—ovarian cancer	0.000381	0.00226	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000374	0.00222	CcSEcCtD
Lubiprostone—Mental disorder—Docetaxel—ovarian cancer	0.000373	0.00221	CcSEcCtD
Lubiprostone—Chest pain—Paclitaxel—ovarian cancer	0.000372	0.00221	CcSEcCtD
Lubiprostone—Myalgia—Paclitaxel—ovarian cancer	0.000372	0.00221	CcSEcCtD
Lubiprostone—Anxiety—Paclitaxel—ovarian cancer	0.000371	0.0022	CcSEcCtD
Lubiprostone—Erythema—Docetaxel—ovarian cancer	0.000371	0.0022	CcSEcCtD
Lubiprostone—Malnutrition—Docetaxel—ovarian cancer	0.000371	0.0022	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00037	0.00219	CcSEcCtD
Lubiprostone—Nausea—Topotecan—ovarian cancer	0.000369	0.00218	CcSEcCtD
Lubiprostone—Discomfort—Paclitaxel—ovarian cancer	0.000368	0.00218	CcSEcCtD
Lubiprostone—Gastritis—Epirubicin—ovarian cancer	0.000367	0.00218	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000366	0.00217	CcSEcCtD
Lubiprostone—Dry mouth—Paclitaxel—ovarian cancer	0.000364	0.00216	CcSEcCtD
Lubiprostone—Diarrhoea—Vinorelbine—ovarian cancer	0.000363	0.00215	CcSEcCtD
Lubiprostone—Dysgeusia—Docetaxel—ovarian cancer	0.000363	0.00215	CcSEcCtD
Lubiprostone—Abdominal distension—Epirubicin—ovarian cancer	0.000361	0.00214	CcSEcCtD
Lubiprostone—Nausea—Melphalan—ovarian cancer	0.000361	0.00214	CcSEcCtD
Lubiprostone—Influenza—Epirubicin—ovarian cancer	0.000359	0.00213	CcSEcCtD
Lubiprostone—Oedema—Paclitaxel—ovarian cancer	0.000357	0.00212	CcSEcCtD
Lubiprostone—Muscle spasms—Docetaxel—ovarian cancer	0.000356	0.00211	CcSEcCtD
Lubiprostone—Shock—Paclitaxel—ovarian cancer	0.000351	0.00208	CcSEcCtD
Lubiprostone—Dizziness—Vinorelbine—ovarian cancer	0.000351	0.00208	CcSEcCtD
Lubiprostone—Nervous system disorder—Paclitaxel—ovarian cancer	0.00035	0.00208	CcSEcCtD
Lubiprostone—Tachycardia—Paclitaxel—ovarian cancer	0.000348	0.00207	CcSEcCtD
Lubiprostone—Skin disorder—Paclitaxel—ovarian cancer	0.000347	0.00206	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000346	0.00205	CcSEcCtD
Lubiprostone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000345	0.00205	CcSEcCtD
Lubiprostone—Anorexia—Paclitaxel—ovarian cancer	0.00034	0.00202	CcSEcCtD
Lubiprostone—Gastritis—Doxorubicin—ovarian cancer	0.00034	0.00202	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000339	0.00201	CcSEcCtD
Lubiprostone—Vomiting—Vinorelbine—ovarian cancer	0.000337	0.002	CcSEcCtD
Lubiprostone—Rash—Vinorelbine—ovarian cancer	0.000335	0.00198	CcSEcCtD
Lubiprostone—Dermatitis—Vinorelbine—ovarian cancer	0.000334	0.00198	CcSEcCtD
Lubiprostone—Abdominal distension—Doxorubicin—ovarian cancer	0.000334	0.00198	CcSEcCtD
Lubiprostone—Headache—Vinorelbine—ovarian cancer	0.000332	0.00197	CcSEcCtD
Lubiprostone—Syncope—Docetaxel—ovarian cancer	0.000332	0.00197	CcSEcCtD
Lubiprostone—Influenza—Doxorubicin—ovarian cancer	0.000332	0.00197	CcSEcCtD
Lubiprostone—Pollakiuria—Epirubicin—ovarian cancer	0.000332	0.00197	CcSEcCtD
Lubiprostone—Palpitations—Docetaxel—ovarian cancer	0.000328	0.00194	CcSEcCtD
Lubiprostone—Weight increased—Epirubicin—ovarian cancer	0.000327	0.00194	CcSEcCtD
Lubiprostone—Loss of consciousness—Docetaxel—ovarian cancer	0.000326	0.00193	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000325	0.00193	CcSEcCtD
Lubiprostone—Cough—Docetaxel—ovarian cancer	0.000324	0.00192	CcSEcCtD
Lubiprostone—Dyspnoea—Paclitaxel—ovarian cancer	0.000318	0.00189	CcSEcCtD
Lubiprostone—Chest pain—Docetaxel—ovarian cancer	0.000316	0.00187	CcSEcCtD
Lubiprostone—Myalgia—Docetaxel—ovarian cancer	0.000316	0.00187	CcSEcCtD
Lubiprostone—Nausea—Vinorelbine—ovarian cancer	0.000315	0.00187	CcSEcCtD
Lubiprostone—Dyspepsia—Paclitaxel—ovarian cancer	0.000314	0.00186	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000313	0.00186	CcSEcCtD
Lubiprostone—Urinary tract infection—Epirubicin—ovarian cancer	0.000311	0.00184	CcSEcCtD
Lubiprostone—Decreased appetite—Paclitaxel—ovarian cancer	0.00031	0.00184	CcSEcCtD
Lubiprostone—Dry mouth—Docetaxel—ovarian cancer	0.000309	0.00183	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000308	0.00183	CcSEcCtD
Lubiprostone—Fatigue—Paclitaxel—ovarian cancer	0.000308	0.00182	CcSEcCtD
Lubiprostone—Pollakiuria—Doxorubicin—ovarian cancer	0.000307	0.00182	CcSEcCtD
Lubiprostone—Pain—Paclitaxel—ovarian cancer	0.000305	0.00181	CcSEcCtD
Lubiprostone—Constipation—Paclitaxel—ovarian cancer	0.000305	0.00181	CcSEcCtD
Lubiprostone—Oedema—Docetaxel—ovarian cancer	0.000303	0.00179	CcSEcCtD
Lubiprostone—Weight increased—Doxorubicin—ovarian cancer	0.000302	0.00179	CcSEcCtD
Lubiprostone—Shock—Docetaxel—ovarian cancer	0.000298	0.00176	CcSEcCtD
Lubiprostone—Nervous system disorder—Docetaxel—ovarian cancer	0.000297	0.00176	CcSEcCtD
Lubiprostone—Tachycardia—Docetaxel—ovarian cancer	0.000295	0.00175	CcSEcCtD
Lubiprostone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000294	0.00174	CcSEcCtD
Lubiprostone—Skin disorder—Docetaxel—ovarian cancer	0.000294	0.00174	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000292	0.00173	CcSEcCtD
Lubiprostone—Anorexia—Docetaxel—ovarian cancer	0.000288	0.00171	CcSEcCtD
Lubiprostone—Urinary tract infection—Doxorubicin—ovarian cancer	0.000288	0.00171	CcSEcCtD
Lubiprostone—Oedema peripheral—Epirubicin—ovarian cancer	0.000283	0.00168	CcSEcCtD
Lubiprostone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000282	0.00167	CcSEcCtD
Lubiprostone—Abdominal pain—Paclitaxel—ovarian cancer	0.000282	0.00167	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000276	0.00163	CcSEcCtD
Lubiprostone—Dyspnoea—Docetaxel—ovarian cancer	0.00027	0.0016	CcSEcCtD
Lubiprostone—Dyspepsia—Docetaxel—ovarian cancer	0.000266	0.00158	CcSEcCtD
Lubiprostone—Decreased appetite—Docetaxel—ovarian cancer	0.000263	0.00156	CcSEcCtD
Lubiprostone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000263	0.00156	CcSEcCtD
Lubiprostone—Oedema peripheral—Doxorubicin—ovarian cancer	0.000262	0.00155	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000261	0.00155	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000261	0.00155	CcSEcCtD
Lubiprostone—Fatigue—Docetaxel—ovarian cancer	0.000261	0.00155	CcSEcCtD
Lubiprostone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000259	0.00153	CcSEcCtD
Lubiprostone—Constipation—Docetaxel—ovarian cancer	0.000259	0.00153	CcSEcCtD
Lubiprostone—Pain—Docetaxel—ovarian cancer	0.000259	0.00153	CcSEcCtD
Lubiprostone—Asthenia—Paclitaxel—ovarian cancer	0.000256	0.00152	CcSEcCtD
Lubiprostone—Mental disorder—Epirubicin—ovarian cancer	0.000252	0.00149	CcSEcCtD
Lubiprostone—Erythema—Epirubicin—ovarian cancer	0.00025	0.00148	CcSEcCtD
Lubiprostone—Malnutrition—Epirubicin—ovarian cancer	0.00025	0.00148	CcSEcCtD
Lubiprostone—Feeling abnormal—Docetaxel—ovarian cancer	0.000249	0.00148	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000247	0.00147	CcSEcCtD
Lubiprostone—Flatulence—Epirubicin—ovarian cancer	0.000246	0.00146	CcSEcCtD
Lubiprostone—Dysgeusia—Epirubicin—ovarian cancer	0.000245	0.00145	CcSEcCtD
Lubiprostone—Diarrhoea—Paclitaxel—ovarian cancer	0.000244	0.00145	CcSEcCtD
Lubiprostone—Muscle spasms—Epirubicin—ovarian cancer	0.00024	0.00143	CcSEcCtD
Lubiprostone—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00024	0.00142	CcSEcCtD
Lubiprostone—Abdominal pain—Docetaxel—ovarian cancer	0.000239	0.00142	CcSEcCtD
Lubiprostone—Dizziness—Paclitaxel—ovarian cancer	0.000236	0.0014	CcSEcCtD
Lubiprostone—Mental disorder—Doxorubicin—ovarian cancer	0.000233	0.00138	CcSEcCtD
Lubiprostone—Ill-defined disorder—Epirubicin—ovarian cancer	0.000232	0.00138	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—ovarian cancer	0.000231	0.00137	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—ovarian cancer	0.000231	0.00137	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—ovarian cancer	0.000228	0.00135	CcSEcCtD
Lubiprostone—Vomiting—Paclitaxel—ovarian cancer	0.000227	0.00135	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—ovarian cancer	0.000227	0.00134	CcSEcCtD
Lubiprostone—Malaise—Epirubicin—ovarian cancer	0.000226	0.00134	CcSEcCtD
Lubiprostone—Rash—Paclitaxel—ovarian cancer	0.000225	0.00133	CcSEcCtD
Lubiprostone—Dermatitis—Paclitaxel—ovarian cancer	0.000225	0.00133	CcSEcCtD
Lubiprostone—Syncope—Epirubicin—ovarian cancer	0.000224	0.00133	CcSEcCtD
Lubiprostone—Headache—Paclitaxel—ovarian cancer	0.000224	0.00133	CcSEcCtD
Lubiprostone—Hypersensitivity—Docetaxel—ovarian cancer	0.000223	0.00132	CcSEcCtD
Lubiprostone—Muscle spasms—Doxorubicin—ovarian cancer	0.000222	0.00132	CcSEcCtD
Lubiprostone—Palpitations—Epirubicin—ovarian cancer	0.000221	0.00131	CcSEcCtD
Lubiprostone—Loss of consciousness—Epirubicin—ovarian cancer	0.00022	0.0013	CcSEcCtD
Lubiprostone—Cough—Epirubicin—ovarian cancer	0.000218	0.00129	CcSEcCtD
Lubiprostone—Asthenia—Docetaxel—ovarian cancer	0.000217	0.00129	CcSEcCtD
Lubiprostone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000215	0.00127	CcSEcCtD
Lubiprostone—Chest pain—Epirubicin—ovarian cancer	0.000213	0.00126	CcSEcCtD
Lubiprostone—Myalgia—Epirubicin—ovarian cancer	0.000213	0.00126	CcSEcCtD
Lubiprostone—Anxiety—Epirubicin—ovarian cancer	0.000212	0.00126	CcSEcCtD
Lubiprostone—Nausea—Paclitaxel—ovarian cancer	0.000212	0.00126	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000211	0.00125	CcSEcCtD
Lubiprostone—Discomfort—Epirubicin—ovarian cancer	0.00021	0.00125	CcSEcCtD
Lubiprostone—Malaise—Doxorubicin—ovarian cancer	0.000209	0.00124	CcSEcCtD
Lubiprostone—Dry mouth—Epirubicin—ovarian cancer	0.000208	0.00123	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—ovarian cancer	0.000208	0.00123	CcSEcCtD
Lubiprostone—Diarrhoea—Docetaxel—ovarian cancer	0.000207	0.00123	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—ovarian cancer	0.000204	0.00121	CcSEcCtD
Lubiprostone—Oedema—Epirubicin—ovarian cancer	0.000204	0.00121	CcSEcCtD
Lubiprostone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000203	0.00121	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—ovarian cancer	0.000202	0.0012	CcSEcCtD
Lubiprostone—Shock—Epirubicin—ovarian cancer	0.000201	0.00119	CcSEcCtD
Lubiprostone—Nervous system disorder—Epirubicin—ovarian cancer	0.0002	0.00119	CcSEcCtD
Lubiprostone—Dizziness—Docetaxel—ovarian cancer	0.0002	0.00119	CcSEcCtD
Lubiprostone—Tachycardia—Epirubicin—ovarian cancer	0.000199	0.00118	CcSEcCtD
Lubiprostone—Skin disorder—Epirubicin—ovarian cancer	0.000198	0.00118	CcSEcCtD
Lubiprostone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000197	0.00117	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—ovarian cancer	0.000197	0.00117	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—ovarian cancer	0.000197	0.00117	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—ovarian cancer	0.000196	0.00116	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000196	0.00116	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—ovarian cancer	0.000195	0.00115	CcSEcCtD
Lubiprostone—Anorexia—Epirubicin—ovarian cancer	0.000195	0.00115	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—ovarian cancer	0.000193	0.00114	CcSEcCtD
Lubiprostone—Vomiting—Docetaxel—ovarian cancer	0.000192	0.00114	CcSEcCtD
Lubiprostone—Rash—Docetaxel—ovarian cancer	0.000191	0.00113	CcSEcCtD
Lubiprostone—Dermatitis—Docetaxel—ovarian cancer	0.000191	0.00113	CcSEcCtD
Lubiprostone—Headache—Docetaxel—ovarian cancer	0.00019	0.00112	CcSEcCtD
Lubiprostone—Oedema—Doxorubicin—ovarian cancer	0.000189	0.00112	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000186	0.0011	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—ovarian cancer	0.000186	0.0011	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000185	0.0011	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—ovarian cancer	0.000184	0.00109	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—ovarian cancer	0.000183	0.00109	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000183	0.00108	CcSEcCtD
Lubiprostone—Dyspnoea—Epirubicin—ovarian cancer	0.000182	0.00108	CcSEcCtD
Lubiprostone—Anorexia—Doxorubicin—ovarian cancer	0.00018	0.00107	CcSEcCtD
Lubiprostone—Nausea—Docetaxel—ovarian cancer	0.00018	0.00107	CcSEcCtD
Lubiprostone—Dyspepsia—Epirubicin—ovarian cancer	0.00018	0.00107	CcSEcCtD
Lubiprostone—Decreased appetite—Epirubicin—ovarian cancer	0.000177	0.00105	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000176	0.00104	CcSEcCtD
Lubiprostone—Fatigue—Epirubicin—ovarian cancer	0.000176	0.00104	CcSEcCtD
Lubiprostone—Pain—Epirubicin—ovarian cancer	0.000175	0.00103	CcSEcCtD
Lubiprostone—Constipation—Epirubicin—ovarian cancer	0.000175	0.00103	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000172	0.00102	CcSEcCtD
Lubiprostone—Dyspnoea—Doxorubicin—ovarian cancer	0.000168	0.000998	CcSEcCtD
Lubiprostone—Feeling abnormal—Epirubicin—ovarian cancer	0.000168	0.000997	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000167	0.000989	CcSEcCtD
Lubiprostone—Dyspepsia—Doxorubicin—ovarian cancer	0.000166	0.000985	CcSEcCtD
Lubiprostone—Decreased appetite—Doxorubicin—ovarian cancer	0.000164	0.000973	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000163	0.000967	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—ovarian cancer	0.000163	0.000965	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—ovarian cancer	0.000161	0.000957	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—ovarian cancer	0.000161	0.000957	CcSEcCtD
Lubiprostone—Abdominal pain—Epirubicin—ovarian cancer	0.000161	0.000956	CcSEcCtD
Lubiprostone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000156	0.000923	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000154	0.000915	CcSEcCtD
Lubiprostone—Hypersensitivity—Epirubicin—ovarian cancer	0.00015	0.000891	CcSEcCtD
Lubiprostone—Abdominal pain—Doxorubicin—ovarian cancer	0.000149	0.000885	CcSEcCtD
Lubiprostone—Asthenia—Epirubicin—ovarian cancer	0.000146	0.000868	CcSEcCtD
Lubiprostone—Diarrhoea—Epirubicin—ovarian cancer	0.00014	0.000828	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000139	0.000825	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—ovarian cancer	0.000135	0.000803	CcSEcCtD
Lubiprostone—Dizziness—Epirubicin—ovarian cancer	0.000135	0.0008	CcSEcCtD
Lubiprostone—Vomiting—Epirubicin—ovarian cancer	0.00013	0.000769	CcSEcCtD
Lubiprostone—Diarrhoea—Doxorubicin—ovarian cancer	0.000129	0.000766	CcSEcCtD
Lubiprostone—Rash—Epirubicin—ovarian cancer	0.000129	0.000763	CcSEcCtD
Lubiprostone—Dermatitis—Epirubicin—ovarian cancer	0.000129	0.000762	CcSEcCtD
Lubiprostone—Headache—Epirubicin—ovarian cancer	0.000128	0.000758	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—ovarian cancer	0.000125	0.00074	CcSEcCtD
Lubiprostone—Nausea—Epirubicin—ovarian cancer	0.000121	0.000719	CcSEcCtD
Lubiprostone—Vomiting—Doxorubicin—ovarian cancer	0.00012	0.000712	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—ovarian cancer	0.000119	0.000706	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—ovarian cancer	0.000119	0.000705	CcSEcCtD
Lubiprostone—Headache—Doxorubicin—ovarian cancer	0.000118	0.000701	CcSEcCtD
Lubiprostone—Nausea—Doxorubicin—ovarian cancer	0.000112	0.000665	CcSEcCtD
